SPONSORED CONTENT: Downstream processing can be the cause of a bottleneck in manufacturing, particularly for complex biologics, leading to a need for simpler platform approaches, according to Kenneth Holbourn from FUJIFILM Biotechnologies.

Following the global launch of the Synchrony S1 PFS system, ten23 health has completed robustness testing to ensure the platform is ready for clients navigating the complexities of drug-device regulations.

By securing the rights to a Phase II dissolvable implant for glaucoma and diabetic retinopathy, targeting the underlying vascular causes of vision loss, Bayer is positioning itself at the forefront of long-acting ocular drug delivery.

With industry reaching the limits of traditional formulation techniques, to overcome solubility and bioavailability challenges, spray-drying is increasingly emerging as a primary development pillar.

By harnessing light-controlled gene expression, Prolific Machines has more than doubled the standard fed-batch CHO productivity benchmark, opening the door to the scalable manufacture of complex biologics.

Philadelphia-based CDMO, PCI Pharma Services, has committed to substantial investments in sterile fill/finish and drug-device combination assembly across its global operations.

The acquisition is expected to create a global powerhouse in women’s health, biosimilars and branded generics with operations in 150 countries, and is set to close in early 2027 pending approvals.

As the industry pivots toward eco-design and green procurement, the whole value chain must align to bridge the gap between environmental targets and manufacturing reality.

From high-speed syringe inspection to sustainable blister production, IMA Group is heading to Düsseldorf with a portfolio of innovations aimed at streamlining the complex journey from drug product to final package.

With this definitive acquisition agreement, the CDMO will expand its presence on the global market with its first European location and will enable greater customer support.

SPONSORED CONTENT: As CDMOs face increasing demand for agility and resilience, Azam Razzaq from FUJIFILM Biotechnologies reveals how the expanded Borealis facility is helping to bridge the gap between clinical supply and commercial reality for sponsors.

The companies have entered into the evaluation agreement to investigate whether circVec circular RNA technology can be delivered to T cells using Acuitas’ targeted lipid nanoparticles.

As smaller batch products become more prominent within drug development, companies are being required to adopt more agile, modular approaches to ensure commercial viability is achievable.

The expansion of the Swiss CDMO’s activities into the Asia Pacific area marks a significant milestone in its global growth and means it will be able to better serve pharma and biotech companies across the region.

In response to the growing demand for in-human trial material, German CDMO Vetter is expanding its clinical manufacturing network with new infrastructure in the U.S. and Austria.

The European Commission has approved dupilumab (Dupixent) as the first targeted therapy for chronic spontaneous urticaria (CSU) in children in the EU, broadening its use in type‑2‑driven inflammatory diseases.

Automation and living contamination control strategies are helping to answer some of industry’s most pressing sterile manufacturing challenges, explains Dr. Laura Moody from Syntegon.

Customized engineering and embedded sensors are helping to turn passive single-use assemblies into intelligent, data-rich assets, reveals Rich Jones from Phillips Medisize.

Automated and single-use technologies are offering companies the transparency and agility needed for the newer, more complex drugs in the pipeline, explains Mike D’Avanzo from Alcami.

While the benefits of continuous manufacturing have been well-documented, regulatory alignment and complex control systems remain barriers to universal adoption, notes Mike Fazio from L.B. Bohle.